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The activation of Hageman factor results from its exposure  to various  insoluble 
particles having negative charges on their surfaces, such as glass, kaolin, extracellular 
membranes, etc., and to enzymes such as trypsin in solution. We have currently found 
that activation of Hageman factor by kaolin is highly inefficient  in the presence of 
plasma, only a small percentage of the Hageman factor being utilized in the reaction 
(1). This led to the speculation that important soluble activators may exist in plasma 
that  could greatly amplify the activation.  Such activators  could be  released  from 
cells at the moment of injury of tissues while others could be activated in the plasma. 
From previous data enzymes would comprise likely candidates for activators in the 
fluid  phase,  and  one might reasonably  suspect  the  involvement  of  those  enzymes 
activated  under  the  same  circumstances  as  Hageman  factor.  One  such  enzyme, 
plasmin, has been shown to activate Hageman factor (2),  a finding that was subse- 
quently  confirmed  (3).  A  similar  capacity  of  two  other  enzymes,  kallikrein  and 
clotting Factor XI (plasma thromboplastin antecedent, PTA) 1, both of which are acti- 
vated directly by Hageman factor, is described  herein.  A key role of kallikrein was 
observed in amplifying the activation of Hageman factor which is essential  for an 
adequate rate of generation of the fibrinolytic and intrinsic clotting systems. 
We  will  also  report  upon  changes  observed  in  the  structure  of Hageman 
factor incurred during activation in fluid phase by plasma enzymes and in solid 
phase  by insoluble,  negatively charged particles  in  the  absence  of detectable 
enzymes. The data form a base for understanding the mechanisms of Hageman 
factor activation in pathologic conditions. 
* This work was supported by U. S. Public Health Service Grant AI-07007, the American 
Heart Association, and the Council for Tobacco Research. 
:~ Recipient  of U. S. Public Health Service Research Career Development Award 1 KO4 
AM 40086-02. 
1 Abbreviations  used in this paper: AGLME,  acetyl-glycine-lysine methyl ester;  BAEe, 
benzoyl-n-arginine ethyl ester;  BSA, bovine serum albumin;  DFP, diisopropyl fluorophos- 
phate; EACA, e-amino-n-caproic acid; OMTI, Ovomucoid trypsin  inhibitor;  PMSF, phenyl 
methyl sulfonyl fluoride; PTA, plasma  thromboplastin  antecedent;  SDS, sodium  dodecyl 
sulfate; TBS, 0.01 M tris(hydroxymethyl)aminomethane  buffer pH 7.4 in 0.15 M NaCI. 
1564  THE JOURNAL OF  EXPERIMENTAL MEDICINE • VOLUME 138,  1973 C. G. COCHRANE~  S. D. REVAK~ AND  K. D. WUEPPER  1565 
Materials and Methods 
Preparation of Proteins.-- 
Hageman factor:  Rabbit  and human  Hageman  factor were  purified  according  to  pre- 
viously published methods (4).  Protein eluting early in the Hageman factor peak (as deter- 
mined by ability to activate prekallikrein upon treatment with trypsin) from the final car- 
boxymethyl Sephadex C-50 column was  chosen for radioisotope labeling with nsI  by the 
Chloramine T  method (5).  80-90% of the protein-bound iodine thus prepared was bound to 
inactive Hageman factor (1).  Varying amounts of this labeled Hageman factor were added 
to cold (unlabeled) aliquots of Hageman factor and the mixture used for activation studies. 
The labeled Hageman factor was stored in aliquots at --70  ° C and thawed just before use. 
Prekallikrein:  Highly purified rabbit and  human prekallikrein were prepared according 
to published methods  (6). The prekallikrein tested in acrylamide gel electrophoresis in the 
presence or absence of sodium dodecyl sulfate (SDS) gave a single protein band when stained 
with Coomassie blue. 
Kallikrein:  Kallikrein was prepared  by trypsin activation of prekallikrein followed by 
inhibition of the trypsin by 50/1 (wt/wt) excess ovomucoid trypsin inhibitor (OMTI) (Worth- 
ington Biochemical Corp., Freehold, N. J.). Generally 0.5/lg trypsin (2X crystallized, Worth- 
ington Biochemical) was employed for each microgram of prekallikrein at pH  7.4.  Activity 
of the kallikrein was then assayed by addition of 3 ml of 1 mM benzoyl-L-arginine ethyl ester 
(BAEe) (Schwartz/Mann Div., Becton, Dickinson and Co., Orangeburg, N. Y.) as described 
previously (6). 
Clotting Factor XI:  Factor XI  (PTA)  was prepared from  human plasma according to 
the  published methodsfi The  Factor  XI  recovered  from  its  final  separatory  procedure, 
Pevikon block electrophoresis (Pevikon, Pharmacia Fine Chemicals, Inc., Piscataway, N. J.), 
was activated by the addition of 1/~g trypsin to 0.3 ml of Factor XI. The quantity of Factor 
XI was in the order of 10-20/~g/ml, but an exact assay of protein was not possible. After in- 
cubation at 37°C for 30 min the trypsin activity was inhibited by the addition of 50/ag OMTI. 
Activity of Factor XI was determined by its ability to hydrolyze BAEe or promote clotting 
in Factor XI-deficient plasma. 
Plasminogen:  Purified human plasminogen was obtmned through the courtesy of Dr. E. 
C. DeRenzo and Dr. P. H. Bell of Lederle Laboratories, Pearl River, N. Y. Plasminogen was 
converted to p]asmin by the addition of  180 U  streptokinase (Lederle Laboratories)  to 40 
#g plasminogen. After 10 mill incubation at 37°C, conversion to plasmin was complete, with 
the final concentration being 4/2g/10/~1 reaction volume. Plasmin activity was assayed in 
fibrin plates. The area of lysed circles was compared quantitatively with those produced by 
standard quantities of plasmin kindly provided by Dr. Alan J. Johnson, American National 
Red Cross Laboratory  (New York University Medical Center, New York).  For each plate 
16 mg human fibrinogen (Nutritional Biochemical Corp.,  Cleveland, Ohio) were added to 2 
ml of tris(hydroxymethyl)aminomethane buffer 0.01  M  pH 7.4 containing 0.15 NaC1 (TBS) 
and heated to 49°C.  E-amino-n-caproic acid  (EACA)  (Sigma Chemical Company, St. Louis, 
Mo.) was added to a concentration of 0.0044 M to prevent the activation by streptokinase of a 
small amount of plasminogen present as a  contaminant of the fibrinogen. By this method, 
as little as 0.2  /lg  (equivalent to 0.007  CTA units)  could be detected.  For  the activation 
studies discussed below, streptokinase-activated plasminogen, or on occasion, standard human 
plasmin, was employed after testing for activity by the fibrin plate method. 
Activation of Hageman factor:  Activation of Hageman factor was generally accomplished 
by the addition of increasing amounts of activator to a constant amount of Hageman factor at 
a pH of 7.4 in a plastic- or silicone-coated glass tube. Reaction volumes were 0.15-0.2 ml and 
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contained from 0.5  to 2.0/ag Hageman factor.  For maximum enzymatic activation 0.5  /~g 
trypsin  (inhibited after the reaction by addition of 50 pg OMTI), 0.5/~g kallikrein, or 3 /zg 
plasmin (incubated at 37 ° C for 30 min) were generally sufficient.  As noted above, the concen- 
tration of Factor XI could not be determined accurately, and the highest dose used was not 
sufficient to cause complete activation of the Hageman factor. Washed kaolin was tested for 
the quantity yielding maximum activation of Hageman factor. Generally, the optimum was 
between 50-250/~g kaolin as determined by preliminary assay.  The kaolin was  incubated 
with the 125I-labeled Hageman factor for 15 min at 22°C with gentle shaking. The reaction 
mixture was generally centrifuged (3,400 rpm for 3 min)  and  the supernate  removed.  More 
than 80% of the Hageman factor was bound to the kaolin as determined quantitatively by 
radiolabeling. Activated Hageman factor was assayed by either its ability to activate 1.25/~g 
(exceptions noted)  rabbit prekallikrein or decrease the clotting time of Factor XII-deficient 
human plasma (4). In the former assay, prekallikrein was converted to kallikrein and the ac- 
tivity of this enzyme assayed  by its capacity to hydrolyze 1 mM BAEe. Data are presented 
as changes in optical density at 253 nm at 37°C over a period of 30 min. 
Physical Methods.-- 
Acrylamide gel electrophoresis:  Acrylamide gels  (7  or  10%,  see below)  containing 0.1% 
SDS  (Bio-Rad Laboratories,  Richmond,  Calif.) were employed for observation of possible 
cleavage products  of  activated  [12~I]Hageman  factor  according  to  described methods  (7). 
Samples of 0.1  ml were applied to gels 8 cm  )<  5 mm and electrophoresis carried out at 4 
mA/tube for 45  min followed by 8 mA/tube for 4 h. At the termination of electrophoresis 
1.2-mm  segments were cut and analyzed for radioactive content. Location of the 125I peaks 
were recorded relative to either [13IX]bovine serum albumin (BSA)  run in the same gel or to 
the tracking dye used  (bromphenol blue) and molecular weights determined by comparison 
with  the  migration  (Rf)  of  protein  markers  (human  IgG,  transferrin,  BSA,  ovalbumin, 
chymotrypsinogen,  cytochrome c)  of known molecular weight  observed in a  separate  gei. 
Generally 7% acrylamide was employed in gels in which native Hageman factor was analyzed. 
Ultracentrifugation in density gradients of sucrose:  Ultracentrifugation studies were carried 
out in a 5-20% linear gradient of sucrose (Schwartz/Mann) in TBS at 65,000 rpm for 8 h or 
45,000  rpm for  16 h.  Fractions containing 10  or 15 drops/tube  were obtained. These were 
generally  assayed  for  Hageman  factor  by  radioisotope  detection  (125I), for  spontaneous 
activity (addition directly to 1.25/.tg prekallikrein), and for precursor,  (activatable Hageman 
factor; activation with 0.2/lg trypsin before addition of prekallikrein as noted above). 
Reduction of disulfide bonds and alkylation:  Proteins in TBS were subjected to reduction 
in 0.02  M  dithiothreitol for 1 h  at room temperature and alkylated by addition of 0.05  M 
iodoacetamide for 30 min at 4°C. 
RESULTS 
Activation  of Purified Hageman Factor on Negatively Charged Particles.- 
Addition  of  plasma  to  glass  or  to  particles  with  negative  charges  leads  to 
binding  and  activation  of  a  portion  of  the  Hageman  factor.  It  has  not  been 
clear whether  the  activation  resulted  from binding  to  the  surfaces  alone or to 
binding  followed  by  subsequent  activation  by  enzymes  in  the  plasma.  To 
examine this question, 0.5  #g highly purified rabbit Hageman factor was added 
to increasing quantities of washed kaolin in TBS as shown in Fig.  1. As noted, 
activation of the Hageman factor resulted,  reaching a  maximum when approxi- 
mately  10/~g kaolin were added.  The decrease in measureable  Hageman factor 
activity in  an  excess of insoluble activator is  apparently  caused  by binding  of C.  G.  COCHRANE,  S.  D.  REVAK,  AND  K.  D.  WUEPPER  1567 
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Fro. 1. Activation of 0.5 pg highly purified Hageman factor by kaolin. Final volume =  0.20 ml. 
the prekallikrein used  in  the  assay to  the  kaolin  and  thereby lost from the 
reaction.  The  diminution  in  activity  does  not  appear  when  acetyl-glycine- 
lysine methylester (AGLME) is used in excess to assay for activity (8). 
Despite  the  activation  of  highly  purified  Hageman  factor  on  negatively 
charged particles, attempts were made to activate the molecule in the presence 
of an inhibitor of kallikrein, Factor XI, and plasmin. These enzymes, known to 
activate Hageman factor (see below), and possibly present in trace amounts, 
are  susceptible  to  treatment  with  phenyl methyl  sulfonyl fluoride  (PMSF). 
Direct assay failed to reveal the presence of plasmin or kallikrein in the prepara- 
tion of rabbit Hageman  factor  to the  hmit of sensitivity, i.e., about 0.1  ug. 
Nevertheless  the  preparation  of  purified Hageman  factor  was  treated  with 
PMSF in concentrations of 10  -2 to 10  -5 M for 10 min at 22°C. The preparations 
were then incubated with 50 #g kaolin followed by washing  of the particles 
twice in TBS. Activation, as determined by prekallikrein activation, was not 
inhibited by treatment of the Hageman factor preparation with PMSF (Table 
I).  In addition,  100  #g kaolin  were added to  0.2 ml Hageman  factor in the 
presence of EACA, 10  -2 M final concentration. After incubation, the supernatant 
fluid was removed and the bound Hageman factor assayed. No diminution of 
activating capacity was noted despite the presence of EACA during activation. 
Inhibition  of binding of [125I]Hageman factor  to kaolin  by plasma:  Previous 
studies  have  demonstrated  that  plasma  inhibits  the  removal  of  Hageman 
factor from  solution  by  kaolin  as  determined  immunologically and  by de- 
creased prekallikrein-activating capacity of the  treated kaolin  (1).  With  the 
availability  of  125I-labeled Hageman  factor,  it  was  important  to  determine 
directly if the binding of Hageman factor to a negatively charged particle was 
inhibited by the presence of plasma or plasma proteins. Accordingly approxi- 
mately 0.05 #g [l~5I]human or [t2"~I]  rabbit Hageman factor was mixed with incre- 
ments  of  plasma deficient in Hageman  factor or prekallikrein (Fletcher trait 
plasma),  normal human plasma,  or human  albumin.  250 ~g kaolin were then 
added and incubation allowed to proceed 15 rain at 22°C.  The kaolin was then 1568  ACTIVATION OF  HAGEMAN FACTOR 
centrifuged  and  washed,  and  the  [125I]Hageman  factor  bound  to  the  kaolin 
measured. As shown in Fig. 2, marked inhibition of binding of Hageman factor 
occurred with both Hageman factor-deficient and normal plasma. No consistent 
difference in inhibition between  the various plasmas  was  noted.  Human  IgG 
and  human  albumin  inhibited  binding  of  Hageman  factor  also,  each  being 
TABLE I 
Activation of Hageman Factor Pretreated "with PMSF on Negatively Charged Particles 
Prekallikrein  activation  Rabbit Hageman factor  Final conc. PMSF  Kaolin  (OD 253 nm) 
pg  M  pg 
0.5  10  -2  50  0.160 
0.5  10  -3  50  0.163 
0.5  10  -4  50  0.178 
0.5  10  -5  50  0.140 
0.5  --  50  0.152 
0.5  --  50  0.160 
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FIO. 2. Inhibition of binding of [125I]rabbit  Hageman factor to 250/ag kaolin by increments 
of normal or Hageman factor-deficient  plasma. Final volume was 150 pl, yielding a dilution 
of the plasma of 1/~ at the highest concentration employed. 
about half as effective as whole plasma on a  weight basis. Pretreatment of the 
kaolin with Hageman  factor-deficient plasma, followed by washing,  inhibited 
binding  as  well  as  when  the  kaolin  was  exposed  to  Hageman  factor  in  the 
presence of plasma (Fig. 2). While rabbit Hageman factor was employed in the 
studies  in  Fig.  2,  binding of human  Hageman  factor was  similarly inhibited. C.  G.  COCHRANE,  S.  D.  REVAK,  AND  K.  D.  WIYEPPER  1569 
As presented previously (1),  the inhibition of uptake of Hageman factor onto 
kaolin by plasma was accompanied by a  decrease in the ability of the kaolin- 
bound  Hageman  factor  to  activate  prekallikrein. 
Activation  of Hageman  Factor in Fluid Phase with Enzymes.- 
With  the  marked  inhibition  of binding  and  activation  of Hageman factor 
to a  negatively charged surface in  the presence of plasma, the possibilities of 
fluid phase activation were explored. Enzymes were first studied that are con- 
verted  to  an  active  state  during,  or  as  a  result  of,  the  initial  activation  of 
Hageman factor. 
Kallikrein:  Human and rabbit Hageman factor, 0.6-1.0  vg, were exposed to 
increments of purified kallikrein of the corresponding and heterologous species 
at  37°C  for  30  rain.  After  treatment,  the  Hageman  factor  was  assayed  for 
activity  of  two  of  its  known  functions,  the  activation  of  prekallikrein  and 
promotion of clotting. Examples of such experiments are shown in Figs. 3 and 
4.  A  dose-response relationship  was  observed between  the  quantity  of kalli- 
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Fio. 3. Activation of rabbit Hageman factor by human kallikrein. Kallikrein or prekalli- 
krein in the amounts shown was added to 0.6 big Hageman factor in 0.05 ml. Mter incubation, 
1.25 big rabbit prekallikrein was added to indicate activation of Hageman factor as noted in 
Materials and Methods. 
krein  added  and  the  activation of Hageman factor.  In Fig.  4,  kallikrein  and 
trypsin are compared on a  weight basis in  their abiity to activate Hageman 
factor.  While  it  was found  that by weight,  trypsin was slightly more active, 
when  compared on a  molar basis, kallikrein possessed greater activity. 
When prekallikrein was substituted  for kallikrein,  the Hageman factor was 
not  activated  to promote clotting.  However, when  doses  as large  as 0.60 pg 
human  prekallikrein  were  incubated  with  Hageman  factor,  some  Hageman 
factor activity did develop as noted in Fig. 3. This may be explained by a trace 
of activity present in either or both the precursor Hageman factor or prekalli- 1570  ACTIVATION  OF HAGEMAN  FACTOR 
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Fa~. 4. Activation of human Hageman factor by human kallikrein and trypsin. Kaliikrein, 
prekallikrein, and trypsin were added to Hageman factor as noted in Fig. 3. Activity of the 
Hageman factor was then assessed  by its ability to promote clotting of Factor XII-deficient 
plasma. The shaded zone represents the range of normal clotting times. 
krein.  A  small  amount  of activity of either reagent  could initiate  a  cyclical 
process of activation. 
In order to gain further evidence that kallikrein was reponsible for the activa- 
tion of Hageman factor, purified kallikrein was subjected to molecular exclu- 
sion  chromatography  on  Sephadex  G-200.  The  various  fractions  were  then 
assayed for their capacity to  activate Hageman factor. As  shown  in  Fig.  5, 
activation of Hageman factor was observed in fractions containing kallikrein. 
Similarly, when kallikrein was  sedimented in  a  gradient of sucrose and  sub- 
jected to electrophoresis in Pevikon, the fractions found to activate Hageman 
factor corresponded to those containing kallikrein activity. 
In  additional  control experiments,  12  ug  rabbit  kallikrein  in  1.0  ml  PBS 
were treated with diisopropyl fluorophosphate (DFP)  (10  -4 M  final concentra- 
tion) and after 10 min at room temperature dialyzed 18 h against three changes 
of PBS, 600 ml each. An identical quantity of untreated kallikrein was similarly 
dialyzed. 0.5 and 1.0/zg of the treated and untreated kallikrein were then added 
to Hageman factor as above. Marked inhibition of the Hageman factor activat- 
ing capacity of kallikrein occurred following treatment with DFP in contrast 
to the control. 
It should be noted that the two other plasma substrates of Hageman factor, 
Factor XI  and  plasminogen proactivator,  were  separated  from human  pre- 
kallikrein  during  elution  from  carboxymethyl Sephadex  during  purification. 
The effect of  kallikrein on Hageman factor was  thereby distinguished  from 
any effect of plasminogen proactivator or Factor XI (PTA). 
Clotting Factor XI,  PTA:  Purified Factor XI  of human  plasma  was  ac- 
tivated  with  trypsin  (see  Materials  and  Methods).  Approximately  1-4  pg C. G. COCHRANE,  S. D. REVAK, AND  K. D. WUEPPER  1571 
were incubated with Hageman factor at 37°C for 30 min. Assays for activation 
of Hageman  factor by addition  of rabbit  prekallikrein  indicated  that  activa- 
tion of the Hageman factor had occurred (Table II). 
Plasmin activation of ttageman factor:  Plasminogen was converted to plasmin 
by the  action  of  streptokinase  as  noted  in  Materials  and  Methods.  Varying 
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FIG. 5. Activation of human Hage,  man factor by human ka]likrein. Purified human kalli- 
krein was chromatographed by molecular exclusion on Sephadex G-200. The elution of kaUi- 
krein is shown in the upper panel. Aliquots of various fractions after dilution 1/~o were acti- 
vated to kallikrein with trypsin and tested  for their  capacity to activate Hageman  factor. 
As shown, the fractions  containing  kallikrein were capable  of activating  Hageman  factor. 
The diluted kallikrein, by itself, hydrolyzed BAEe only weakly (lower panel). 
TABLE II 
Activation of Human Hageman Factor (HHF) by Active Factor XI (PTA) 
PTA  HHF  Prekallikrein activation (253 nm) 
50  100  0.143 
50  100  0.136 
50  --  0.064 
50  --  0.065 
--  100  0.018 
--  100  0.025 
quantities of plasmin were then exposed to 0.6-1.0 ~g human Hageman factor. 
In confirmation of previous studies (2, 3) activation of Hageman factor ensued 
(Fig.  6).  Streptokinase  alone  or  plasminogen  not  treated  with  streptokinase 
failed to activate the Hageman factor. 
Comparison of the capacities  of kallikrein,  Factor XI,  and  plasmin to  activate 
ttageman  factor:  While  accurate  comparisons  of  kallikrein,  plasmin,  and 
Factor XI  to activate  Hageman factor are  not yet possible  (see Discussion), 1572  ACTIVATION  OF  HAG~EMAN  FACTOR 
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FIG. 6. Activation of human Hageman factor with plasmin. Plasmin was activated from 
plasminogen by streptokinase (see Materials and Methods). Activity of Hageman factor is 
expressed by its prekallikrein-activating capacity. The plasmin did not activate prekallikrein 
directly. 
it was deemed important to gain some preliminary data on the relative capacities 
of these enzymes. Accordingly, varying amounts of human kallikrein,  plasmin, 
and Factor XI were incubated with 0.5  pg of highly purified human Hageman 
factor. The activity of Hageman factor was tested by activation of prekallikrein. 
Assays of BAEe  hydrolysis were performed at  20  min.  The quantities  of en- 
zymes used to activate Hageman factor and the amount of prekallikrein  used 
in the assay of the Hageman factor activity were selected to yield a  linear in- 
crease in BAEe hydrolysis between 15  and 30 min incubation time. In the 20- 
min period the comparative results, expressed as the pM BAEe hydrolyzed per 
minute  were  as  follows:  kallikrein  (0.13  pg)-36.8  #M  BAEe;  and  plasmin 
(1.47  pg)-36.9 ~M BAEe. Factor XI was less active than plasmin as calculated 
using the maximal possible quantity of Factor XI present. The figures are in- 
accurate in that the quantity of Factor XI was below that required for precise 
protein determinations.  In each case,  the background hydrolysis of BAEe  by 
the  enzyme used  to  activate Hageman factor was subtracted  from the  total. 
This amount was in each case quite  small, as quantities of the activating en- 
zymes were kept at a minimum. 
Kallikrein was therefore found to be about 11 times more active than plasmin, 
and more than 10 times more active than Factor XI in its capacity to activate 
Hageman factor.  As noted previously, kallikrein is slightly more active  than 
trypsin on a molar basis. However it is clear that for truly quantitative values, 
an assay of primary Hageman factor is essential.  One such assay is being de- 
veloped  (8). 
Changes in  Physical  Characteristics of ttageman  Factor Accompanying  Ac- 
tivation.- 
Molecular  characteristics of ttageman  factor  activated with  particles bearing 
negatively charged surfaces:  [125I]human  and  [l~I]rabbit Hageman factor, con- 
taining  approximately  0.5-1  pg  Hageman  factor,  were  exposed  to  250  pg 
kaolin. After incubation with shaking at 22°C for 15 rain, 88-90 % of the human C. G. COCHRANE,  S. D. REVAK,  AND  K. D. WUEPPER  1573 
Hageman factor, and 93-95 % of the rabbit protein became firmly bound to the 
kaolin and resisted removal by washing in TBS. To find if the bound Hageman 
factor was fully activated, the particles containing Hageman factor were ex- 
posed  to  the fluid phase  activators,  trypsin  and  kallikrein.  Neither  enzyme 
augmented the activity of the Hageman factor. In addition, the activity of the 
kaolin-bound Hageman factor was identical to that generated maximally when 
an equal quantity of Hageman factor was treated with kallikrein or trypsin in 
solution. 
To  elute  the  [125I]Hageman factor from the  kaolin,  the particles were  ex- 
posed to 0.3 % SDS which resulted in elution of 67 % of the bound Hageman 
factor. The eluted protein was then examined in SDS acrylamide gel electro- 
phoresis. A typical pattern is shown in Fig. 7. All of the [12~I]Hageman factor 
~  24  90,000 
....  5'0 
Section Number 
FIG. 7. E]ectrophoresis  in %DS acz~lamide gel of [nSI]rabbit Hageman factor eluted from 
kaolin by 0.3%  SDS.  67% of the Hageman factor was eluted from the particles.  As noted, 
the molecule eluted from kaolin in its native, 90,000  mol wt form, i.e., without evidence of 
cleavage.  Similar results were obtained with [12~I]human Hageman factor. 
was  recovered  in  the  mol  wt  range  of  80,000  (human)  to  90,000  (rabbit). 
Cleavage to smaller tool wt fragments was not observed.  Milder methods of 
removing  the  protein  from kaolin  or  other  negatively charged  particles,  in 
which activity of the  solubilized Hageman factor could be  tested,  were  not 
successful. 
Molecular characteristics of rabbit Hageman factor activated in fluid phase with 
enzymes:  A  comparison  was  made  of  the  physical  characteristics  of  the 
Hageman factor molecule accompanying activation by trypsin, kallikrein and 
plasmin,  and during spontaneous activation accompanying aging.  [12q]rabbit 
Hageman factor  (0.2 ~g in 0.1  ml)  was activated with trypsin  (0.2-0.5  #g), 
kallikrein (0.2-1.25  #g), and plasmin (2-30 #g)  for 1.5, 5,  15, and 30 rain. In 
each case the degree of activation was assessed,  and changes in physical prop- 
erties studied by SDS acrylamide gel and ultracentrifugation in a  gradient of 
sucrose.  In the latter case,  the degree of activity of the Hageman factor could 
be determined in each eluted fraction of the sedimentation tube. As noted in 
Fig. 8, when trypsin was used to activate the [l~SI]rabbit Hageman factor, the 
sedimentation rate was lowered from 4.5  to  2.6S  over a  30-min period. The 
fragmentation of the molecule was accompanied by activation. Active Hage- 1574  ACTIVATION  O]~  I-IAGEMAN FACTOR 
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FIG. 8.  Sedimentation of [i~I]rabbit Hageman factor in a gradient of sucrose before and 
after treatment with 2/~g trypsin for the time periods shown. The 4.5S  marker consisted of 
[z31I]BSA incorporated in each sample as an internal marker. Active Hageman factor (solid 
bars)  was tested by addition of the fractions directly to prekallikrein. Activatable Hageman 
factor was assayed by treatment with trypsin and then OMTI preceding the addition of pre- 
kallikrein. 
man factor was found only in fractions at 2.6S and not at 4.5S, with increasing 
quantities of active Hageman factor appearing at 2.6S  as more of the native 
molecule was cleaved. Activatable (native) Hageman factor, measureable only 
at 4.5S, was lost over the 30-rain period as active Hageman factor appeared at 
2.6S.  There was  no  evidence of molecules lying intermediate to those at 4.5 
and 2.6S  as demonstrated by radioactivity or biologic activity. The apparent 
cleavage of Hageman factor accompanying treatment and activation by trypsin 
was supported by assays of the reactions in acrylamide gel  electrophoresis in 
SDS as shown in Fig. 9.  Treatment with trypsin was associated with cleavage 
of the  rabbit protein  to 30,000  mol wt fragments.  Recent experiments to be 
reported  separately indicate  a  more  complex pattern  of cleavage of human 
Hageman factor by trypsin. 
By  contrast,  when  [~2~I]rabbit Hageman  factor was  treated  with  the  two 
other enzymes, plasmin and rabbit kallikrein, there was no apparent change in 
the sedimentation rate and/or position in electrophoresis of the molecule in SDS 
acrylamide gel.  In  Fig.  10  is  shown  the  sedimentation profile of  [~2~I]rabbit 
Hageman factor treated with plasmin  (16 pg)  and rabbit kallikrein  (4.2  pg). 
As noted, the peak of 125I activity sedimented at 4.5S (determined by [I~II]BSA 
standard which was incorporated as an internal marker in each sample). There 
was no shift of the 125I to 2.6S in contrast to the decrease in sedimentation rate 
of [l~5I]Hageman  factor treated with trypsin as noted in Fig. 8. The activated C.  G.  COCHRANE~  S.  D.  REVAK~ AND  K.  D.  WUEPPER  1575 
Hageman  factor was  detected  in  a  peak  at  4.5S  after  treatment  with  both 
plasmin  and kallikrein. These sedimentation patterns are identical to that of 
untreated Hagernan factor (Fig.  10). 
When  the  [z2~I]rabbit Hageman factor after treatment  with kallikrein and 
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FIG. 9.  Electrophoresis of [z2SI]rabbit  Hageman factor in SDS acrylamide gels before and 
after treatment with trypsin for 30 min (as in Fig. 8). The [z25I]Hageman factor is converted 
from  a  peak  at  90,000 to 30,000  mol wt. 
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FIG. 10. Sedimentation of [125I]rabbit Hageman factor in a gradient of sucrose before and 
after treatment with 16 pg plasmin or 4.2 gg rabbit kallikrein (see Materials and Methods). 
The various fractions were tested for Hageman factor activity as in Fig. 8. Activity was found 
in the peak at 4.5S in the enzyme-treated preparations (middle and lower panels) with neces- 
sity of further activation with trypsin as in the top panel. The Hageman factor used for tests 
with kaUikrein was the same used in the studies of Fig. 8, yielding a slightly different pattern 
on sedimentation than that of the upper and middle panels. 1576  ACTIVATION  OF  I-IAGEMAN  FACTOR 
plasmin was subjected to electrophoresis in SDS acrylamide gels (Fig. 11), the 
tack of cleavage of the Hageman factor into large fragments was confirmed. It 
should be noted that small fragments might not be detected, especially those 
lacking tyrosine. Virtually all of the radiolabeled protein remained at 90,000 
mol wt. It was possible that the rabbit Hageman factor molecule was cleaved 
by plasmin or kallikrein but failed to dissociate by virtue of intrachain disulfide 
bridges.  To  test  this,  rabbit  Hageman factor  was  treated  with  plasmin  or 
kallikrein and then subjected to reduction in 0.02 M  dithiothreitol followed by 
alkylation with iodoaeetamide. The molecule upon reduction dissociated into 
fragments of approximately 30,000  mol wt as determined in SDS  acrylamide 
electrophoresis.  These  fragments were  identical in  size  to  those obtained by 
reduction of the native molecule. Thus, enzymatic cleavage had probably not 
occurred between intrachain disulfide bridges. 
Experiments were performed to find if factors in plasma could cleave rabbit 
Hageman factor activated by kallikrein or affect the fragments obtained after 
treatment with trypsin. Accordingly, [l~SI]rabbit Hageman factor was activated 
by those enzymes as noted above. The active material was then incubated with 
fresh,  nonchelated  rabbit  plasma  obtained  by  rapidly  sedimenting  rabbit 
arterial  blood in plastic  without anticoagulants. Equal  volumes of activated 
Hageman factor and plasma were employed. After incubation at 37°C  for 20 
min and removal of any formed fibrin by centrifugation, the possible fragmenta- 
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Fie,.  11.  Electrophoresis of [125I]rabbit Hageman factor in SDS acrylamide gel before  and 
after  treatment  with plasmin and kallikrein as in Fig.  10.  The  small amount of  Hageman 
factor  that  had spontaneously converted  to  the 30,000  mol wt degradation product in the 
control test did not increase after treatment with plasmin or kallikrein. C.  G.  COCHRANE,  S  D.  REVAK,  AND  K.  D.  WUEPPER  1577 
tion of the 125I-labeled protein was assayed by ultracentrifugation in a gradient 
of sucrose.  The Hageman factor activated by kallikrein and exposed to plasma 
did not appear  in  the  2.6S  zone,  but instead sedimented with a  velocity of 
6-7S. Trypsin-cleaved fragments of 2.6S, upon exposure to plasma sedimented 
at approximately 4.5S. Presumably the activated molecule became bound to an 
inhibitor in plasma, or had aggregated, accounting for the greater rate of sedi- 
mentation. 
In  contrast  to  the  observations with the rabbit protein,  human Hageman 
factor, activated by plasmin and kallikrein, was found to be  cleaved during 
activation. Upon treatment with human kallikrein or plasmin, human Hage- 
man factor was activated and cleaved into fragments of approximately 52,000, 
40,000, and 28,000 tool wt as determined by SDS electrophoresis. These results, 
together with a study correlating activity with the fragments, will be presented 
separately. 
DISCUSSION 
Two  major  considerations  emerge  from  these studies on the activation  of 
Hageman  factor: 
The Activation  of Hageman  Factor in Fluid-Phase  and the Importance  of this 
Mechanism  in  the  Initiation  of  the  Kinin-Forming,  Intrinsic  Clotting, and 
Fibrinolytic Systems.-- 
A comparison has been made between two general mechanisms of activating 
Hageman factor, i.e., that rendered by an insoluble negatively charged surface 
such as kaolin or glass which might be termed solid-phase activation, and that 
induced  enzymatically in  free  solution  which  might  be  called  fluid-phase 
activation. 
Regarding solid-phase activation, the present and previous data from this 
laboratory (1) indicate that the binding and activation of Hageman factor by 
negatively charged surfaces is greatly inhibited by plasma. The combined data 
indicate that only a  small percentage of the available Hageman factor in un- 
diluted plasma  is  bound  and  activated  bv  250  /~g of  kaolin. While  greater 
amounts of kaolin remove more Hageman factor from plasma,  the effective 
activating surface provided by 250/~g of kaolin is greater than that provided by 
two known tissue activators of Hageman factor, vascular basement membranes 
and collagen (unpublished observation). Total inhibition in solid-phase activa- 
tion results from a combination of inhibition of binding of Hageman factor to 
the  surface by plasma proteins  and  inhibition of  the  activity of  the  bound 
Hageman factor by natural inhibitors in plasma. 
These  findings,  together  with  data  derived  from studies  on prekallikrein- 
deficient plasma noted below,  stress the importance of the fluid-phase activa- 
tion of Hageman factor. It was thought probable  that important fluid-phase 
activators might be found among the enzymes set into motion by the  same 
process inducing the activation of Hageman factor. The natural substrates of 1578  ACTIVATION  OF  HAGEMAN  FACTOR 
Hageman  factor  were  therefore  examined  initially  and  it  was  found  that 
kallikrein and clotting Factor XI activate Hageman factor. Plasmin, which is 
activated secondarily, also induced activation of Hageman factor as observed 
previously (2,  3).  The capacity of isolated plasminogen activator to  activate 
Hageman factor was not tested in the present study. 
But which of these three fluid-phase activators is most significant? The semi- 
quantitative comparisons in the present studies indicate that kallikrein is over 
10-fold more active than plasmin and clotting Factor XI which suggests that 
kallikrein plays the most significant role.  This suggestion is supported by the 
recent studies in this laboratory by Wuepper (9) employing plasma deficient in 
prekallikrein (Fletcher trait plasma)  (10, 11). Prekallikrein is absent from the 
Fletcher  trait plasma  by both  functional and  immunochemical assays. This 
plasma exhibits a prolongation of clotting time, a failure to generate kinin, and 
globulins derived from Fletcher trait plasma fail to form plasmin upon exposure 
to  glass  or  kaolin.  These  deficiencies  were  readily corrected  by  addition of 
purified human prekallikrein. The data indicate that prekallikrein is essential 
for generation of not only the kinin-fonning system, but the intrinsic clotting 
and fibrinolytic systems as well. Support for this concept stems from the find- 
ing that purified kallikrein promotes clotting of normal plasma (12). 
It would appear that insufficient Hageman factor is activated in solid phase 
when prekallikrein-deficient plasma contacts glass tubes for the generation of 
adequate  amounts of active Factor XI  to initiate clotting. Possibly, for the 
same reason, the rate of plasmin formation is also low. However, in the presence 
of prekallikrein, the small amount of bound, activated Hageman factor con- 
verts prekallikrein  to  its  active form and  the  kallikrein activates  additional 
Hageman factor in fluid phase. The Hageman factor activated in solution then 
generates sufficient active Factor XI for a normal rate of clotting to occur, and 
accelerates  the  formation of plasminogen activator, plasmin,  and  additional 
kallikrein. 
A scheme of activation of Hageman factor in solid and fluid phase is shown 
in Fig.  12. The heavy arrow denotes the greater degree of activation exerted 
by activation in fluid phases. The significance of kallikrein is underscored. Of 
importance in this hypothesis is  the finding that kallikrein does not generate 
directly Factor XI or plasmin activity from the respective precursor molecules 
(unpublished  observations).  Whether  kallikrein  will  activate  plasminogen 
proactivator has not been tested. 
Despite  the apparent  importance of reciprocal activation of Hageman fac- 
tor in the stimulation of the intrinsic clotting, kinin-and plasmin-forming sys- 
tems, an accurate appraisal of the role of kallikrein vs. plasmin and Factor X1 
will  require information of the precise  quantity of each in plasma,  and their 
rates of activation by Hageman factor and inhibition by natural inhibitors in 
plasma. C. G. COCHRANE,  S. D. REVAK~ AND  K. D. WUEPPER 
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FIO. 12. Scheme  of the activation of Hageman factor in solid and fluid phases. The impor- 
tance of kallikrein in fluid-phase activation of Hageman factor is noted by the accentuated 
arrows. 
Structural Changes Accompanying Activation of the ttageman Factor Molecule.-- 
Molecular changes after solid-phase activation of ttageman factor:  The activa- 
tion of Hageman factor on insoluble, negatively charged surfaces such as pro- 
vided by glass,  kaolin, celite, and diatomaceous earth has been recognized for 
many years from the data of Margolis (13). The observations led to the hypothe- 
sis that Hageman factor unfolds partially on the negatively charged surface to 
induce  its  activation.  Pretreatment  of the  surfaces  with positively  charged 
molecules prevents activation of the Hageman factor (14-16), underscoring the 
importance of the negative surface charge. However it has not been clear whether 
activation resulted from unfolding of the molecule, or from enzymatic cleavage 
by plasma constituents after it became bound. The possibility that enzymatic 
action could account for the activation must be considered in view of the data 
presented herein and since in previous studies  activation of native Hageman 
factor on  insoluble  surfaces  has  been performed with  whole plasma  or with 
partially  purified  fractions  containing  Hageman  factor.  The present  experi- 
ments support the view that Hageman factor can be activated on a negatively 
charged surface independently of external enzymatic activity. The conclusion 
is supported by the findings that Hageman factor, prepared in highly purified 
form, free of other clotting agents (4) plasmin and kallikrein, was readily bound 
to and activated by kaolin; that activation was noted even after the Hageman 1580  ACTIVATION OF  HAGEMAN  FACTOR 
factor was pretreated with DFP and PMSF,  treatment designed to inactivate 
enzymes of the plasma known to activate the Hageman factor, and that activa- 
tion also occurred in the presence of EACA. In addition, Hageman factor added 
to and activated by kaolin in purified form, was recovered in its native size, 
i.e., 80,000--90,000  mol wt in eluates of the kaolin. In this regard, it must be 
recalled  that  Hageman  factor,  exposed  to  kaolin  in  the  presence  of  whole 
plasma and eluted with NaC1 is cleaved into smaller mol wt fragments some of 
which  possess  biologic  activity  (17).  The  molecule  bound  to  the  negatively 
charged surface is  apparently particularly  vulnerable  to proteolytic cleavage 
since rabbit as well as human Hageman factor is cleaved by plasma constituents 
when bound to kaolin. 
These data therefore support the earlier premise (13)  that upon binding of 
Hageman factor to a negatively charged surface, conformational changes occur 
that  allow  combination  with  its  natural  substrates,  prekallikrein,  clotting 
Factor XI,  and plasminogen activator.  As  opposed to previous theories  (18) 
data from this laboratory have indicated that  the  action of activated Hage- 
man factor on prekallikrein and clotting Factor XI is one of an enzyme-sub- 
strate  reaction.  Hageman  factor activates  prekallikrein  and  clotting  Factor 
XI by partial proteolytic cleavage (6,  19); it hydrolyzes synthetic substituted 
lysine methyl esters; its action is blocked by certain inhibitors of trypsin (20); 
and, as has recently been found in this laboratory, Hageman factor activated 
on a negatively charged surface (kaolin)  cleaves the synthetic ester AGLME, 
a reaction that is blocked by pretreatment of the active Hageman factor with 
DFP  (8). Thus, Hageman factor appears to acquire esterolytic activity under 
these conditions while retaining full molecular size. 
Changes in the molecular structure of ttageman factor after fluid-phase activa- 
tion:  Hageman factor, activated in fluid phase by kallikrein or plasmin, was 
cleaved at three positions in the case of the human protein while evidence of 
cleavage  of  rabbit  Hageman  factor  during  activation  was  not  obtained2 
In  studies  to  be  published  separately,  clotting  and  prekallikrein  activating 
capacities were associated with  the fragments.  It  is  not clear, however, that 
cleavage is  essential  to  activation of the molecule in fluid phase.  Donaldson 
and Ratnoff (21)  observed a marked increase in sedimentation rate of human 
Hageman factor that  was  activated with  ellagic acid.  An  increase in  size  of 
the  molecule,  presumably  by  aggregation,  was  not  observed  in  the  present 
studies. In addition we have been unable to maintain ellagic acid in a soluble 
form at 10-4-10  -5 M  at 4°C, the temperature at which the ultracentrifugation 
is conducted. 
Repeated measurements of the activated rabbit molecule by ultracentrifuga- 
3 Revak, S. D., C. G. Cochrane, and A. Johnston. 1973. Structural changes accompanying 
activation of human Hageman factor. Submitted for publication. C.  G.  COCHRANE,  S.  D.  REVAK,  AND  K.  D.  WUEPPER  1581 
tion and by electrophoresis in SDS acrylamide gel indicated that rabbit Hage- 
man factor retained its native size of 90,000 mol wt. In addition, cleavage of 
peptide bonds between an intrachain disulfide bridge had apparently not taken 
place  since  reduction  and  alky]ation  of  the  plasmin  or  kallikrein-activated 
Hageman factor did not result in fragmentation of the molecule. These data 
contrasted with active rabbit Hageman factor resulting from treatment with 
trypsin in which the fragments possessing biologic  activity were recovered in 
the region of 2.6S (Fig. 8) with a mol wt of 30,000. It is apparent that proteolytic 
activity by kallikrein is essential, nevertheless, since prekallikrein did not in- 
induce activation of the Hageman factor, and since pretreatment of kallikrein 
with  diisopropylfluorophosphate  prevented  its  action  on  tiageman  factor. 
The results suggest that cleavage Of a small, as yet undetected, fragment takes 
place when kallikrein or plasmin activate rabbit Hageman factor. The loss of a 
small fragment may also accompany activation with trypsin. Such a  cleavage 
fragment would probably be smaller than 2,500 tool wt since little difference in 
size is observed in the parent molecule after activation with kallikrein or plasmin. 
With such restricted cleavage apparently essential for activation with kalli- 
krein and plasmin, and with no fragmentation observable after activation with 
kaolin, the question must be raised whether cleavage into 30,000-40,000  tool 
wt fragments is  essential for activation even with trypsin,  or whether such 
fragmentation is  a  secondary phenomenon. 
SUMMARY 
The activation of Hageman factor in solid and fluid phase has been analyzed. 
Activation of highly purified Hageman factor occurred after it interacted with 
and became bound to a negatively charged surface. Activation was observed in 
the absence of enzymes that are inhibitable with diisopropylfluorophosphate, 
phenyl methyl sulfonyl fuoride  and e-amino-n-caproic  acid.  The  binding  of 
[12~I]Hageman factor to the negatively charged surface was markedly inhibited 
by plasma or purified plasma proteins. 
Activation of Hageman factor in solution (fuid phase)  was obtained with 
kallikrein,  plasmin,  and  Factor  XI  (plasma  thromboplastin  antecedent). 
Kallikrein was  greater  than  10  times more  active  in  its  ability to  activate 
Hageman factor than plasmin and Factor XI. The data offer a plausible ex- 
planation for the finding that highly purified kallikrein promotes clotting of 
normal  plasma.  In  addition,  the  combined  results  of  this  and  previously 
reported data from this laboratory indicate that the reciprocal  activation of 
Hageman factor by kallikrein in fluid phase  is  essential for normal  rate  of 
activation of the intrinsic-clotting, kinin-forming, and fibrinolytic systems. 
Activation of Hageman factor was associated with three different structural 
changes in the molecule: (a) Purified Hageman factor, activated on negatively 
charged surfaces retained its native mol  wt  of  80-90,000.  Presumably a  con- 1582  ACTIVATION  OF  HAGEMAN  FACTOR 
formational change accompanied activation. (b) In fluid phase, activation with 
kallikrein  and plasmin did not result in cleavage of large fragments of rabbit 
Hageman factor, although the  activation required  hydrolytic capacity of the 
enzymes. (c) Activation of human Hageman factor with kallikrein or plasmin 
was  associated  with  cleavage of  the  molecule  to  52,000,  40,000,  and  28,000 
tool wt fragments. Activation of rabbit Hageman factor with trypsin resulted 
in  cleavage of the molecule  into three  fragments,  each  of  30,000  tool  wt as 
noted previously. This major cleavage occurred simultaneously with activation. 
The authors wish to acknowledge the capable assistance of Mr. Alan Johnston and the 
generous supplies of Hageman deficient blood from Mrs. Gunda Hiatt. 
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